The present invention relates to pharmaceutical composition of calcium channel blocker for the method of treatment of hepatitis C in humans. The methods of the present invention can be used in patients with hepatitis C administering calcium channel blocker such as Isradipine, optionally in combination with one or more anti-hepatitis C drugs.
